BIOA: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-54,662	-34,491
Stock-based compensation expense	8,969	6,178
Depreciation expense	144	95
Loss on extinguishment of debt	0	0
Non-cash interest expense	156	140
Non-cash lease expense	115	113
(gain) loss from changes in fair value on warrants	-6	-48
Accounts receivable	515	603
Prepaid expenses and other current assets	1,481	1,045
Other assets	-13	-3
Accounts payable	3,095	-550
Accrued expenses and other current liabilities	-4,766	-4,224
Deferred revenue	-4,438	-2,900
Deferred grant income	0	-
Net cash used in operating activities	-53,376	-37,332
Purchase of property and equipment	607	585
Purchases of marketable securities	114,431	101,544
Maturities of marketable securities	34,250	8,500
Net cash used in investing activities	-80,788	-93,629
Proceeds from series d issuance	0	0
Issuance costs paid on series d issuance	0	0
Proceeds from initial public offering, net of underwriting discounts and commissions	0	-
Issuance costs paid on initial public offering and private placement	0	-
Proceeds from issuance of common shares through private placement, net of placement agent fees	0	-
Term loan principal payments	4,500	3,000
Deferred offering costs paid	44	0
Proceeds from issuance of common shares upon stock option exercises	0	0
Net cash (used in) provided by financing activities	-4,544	-3,000
Effect of changes in exchange rate on cash and cash equivalents	-68	-58
Net (decrease) increase in cash and cash equivalents	-138,776	-134,019
Cash and cash equivalents at beginning of period	354,349	-
Cash and cash equivalents at end of period	215,573	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

BIOA: the cashflow